COLLABORATIVE DEVELOPMENT AND COMMERCIALIZATION AGREEMENT between AMERIMMUNE LLC and HISTOGEN, INC. Dated as of 26 October 2020Collaborative Development and Commercialization Agreement • October 27th, 2020 • Histogen Inc. • Pharmaceutical preparations • California
This Collaborative Development and Commercialization Agreement (the “Agreement”) is entered into as of 26 October 2020 (the “Effective Date”) by and between Amerimmune LLC, a Virginia limited liability company with a place of business at 11212 Waples Mill Rd, Suite 100, Fairfax, Virginia 22030 (“Amerimmune”), and Histogen, Inc., a Delaware corporation with a place of business at 16745 West Bernardo Drive, Suite 200, San Diego, California 92127 (“Histogen”). Amerimmune and Histogen may each be referred to herein by name or as a “Party”, or, collectively, as the “Parties.”
